Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection
Roche (Switzerland) · Novartis (Switzerland) · +2 more institutions
Abstract
A prospective study of patients with biopsy-confirmed nodal metastases with a clip placed in the sampled node was performed. After neoadjuvant therapy, patients underwent axillary surgery and the pathology of the clipped node was compared with other nodes. Patients undergoing TAD had SLND and selective removal of the clipped node using iodine-125 seed localization. The FNR was determined in patients undergoing complete axillary lymphadenectomy (ALND).
Of 208 patients enrolled in this study, 191 underwent ALND, with residual disease identified in 120 (63%). The clipped node revealed metastases in 115 patients, resulting in an FNR of 4.2% (95% CI, 1.4 to 9.5) for the clipped node. In patients undergoing SLND and ALND (n = 118), the FNR was 10.1% (95% CI, 4.2 to 19.8), which included seven false-negative events in 69 patients with residual disease. Adding evaluation of the clipped node reduced the FNR to 1.4% (95% CI, 0.03 to 7.3; P = .03). The clipped node was not retrieved as an SLN in 23% (31 of 134) of patients, including six with negative SLNs but metastasis in the clipped node. TAD followed by ALND was performed in 85 patients, with an FNR of 2.0% (1 of 50; 95% CI, 0.05 to 10.7).
Citation impact
- FWCI
- 28.69
- Percentile
- 100%
- References
- 24
Authors
20- ASAbigail S. Caudle
Roche (Switzerland), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Varian Medical Systems (Germany)
- WYWei Yang
Roche (Switzerland), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Varian Medical Systems (Germany)
- SKSavitri Krishnamurthy
Roche (Switzerland), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Varian Medical Systems (Germany)
- EAElizabeth A. Mittendorf
Roche (Switzerland), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Varian Medical Systems (Germany)
- DMDalliah M. Black
Roche (Switzerland), Novartis (Switzerland), The University of Texas MD Anderson Cancer Center, Varian Medical Systems (Germany)
Topics & keywords
- Medicine
- Breast cancer
- Axillary Lymph Node Dissection
- Sentinel node
- Neoadjuvant therapy
- Axilla
- Biopsy
- Lymphadenectomy
- Good health and well-being